The University of Oxford team running the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which recruited over 4,000 patients, have…

Qynapse Inc., a medical technology company with a commercialized Artificial Intelligence (AI) powered neuroimaging analysis platform for central…

Pfizer Inc. and BioNTech SE announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine…

Bristol Myers Squibb announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3…

Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for…

EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10-µg…

Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use…

The report published by Economist Impact and sponsored by Daiichi Sankyo Europe, confirms that people who have tested positive for COVID-19 are…

Labs Across Canada Can Now Gain Speed, Cost-Efficient Scalability, and Consistency in a Hands-Free Swab Processing Workflow Rhinostics, Inc., an…

Shionogi & Co., Ltd. (hereafter “Shionogi”) announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress…